The MOMENTUM Study - The Multiple OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac

The MOMENTUM Study - The Multiple OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac - MOMENTUM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52371

Enrollment

10000

Registered

2018-12-19

Start date

2019-02-13

Completion date

Unknown

Last updated

2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Patient is to undergo or has completed imaging or is eligable for treatment procedures on an MR-Linac; - Patient provides written, informed consent; - Patient is 18 years old or older.

Exclusion criteria

Exclusion criteria: MRI exclusion criteria, including - MRI contraindications as per usual clinical care, such as (possible) pregnancy, claustrophobia and metal or electronic implants not compatible with MRI;

Design outcomes

Primary

Measure	Time frame
MOMENTUM will collect technical and clinical patient data. The technical patient data is defined as data generated by (the use of) the MR-Linac and will include data collection during scans performed during routine care as well as research MRIs. Clinical data will be categorized into six classes: demographic, disease characteristics, treatment classifiers, toxicity outcomes, cancer control outcomes and PROs.	—

Measure

Time frame

MOMENTUM will collect technical and clinical patient data. The technical patient data is defined as data generated by (the use of) the MR-Linac and will include data collection during scans performed during routine care as well as research MRIs. Clinical data will be categorized into six classes: demographic, disease characteristics, treatment classifiers, toxicity outcomes, cancer control outcomes and PROs.

—

Countries

Netherlands

Contacts

Public ContactT. Leer

Universitair Medisch Centrum Utrecht

t.leer@umcutrecht.nl0631118102

Outcome results